AGENDA 2023

We are delighted to publish the 2023 Agenda below and will be updating the final presentation topics as they are confirmed, so please check back regularly. 

The E-Cigarette Summit is coming back to Washington D.C on the 16th May 2023.  All speakers are scheduled to present in person but the event is fully hybrid and you can participate virtually if you are  unable to join us in in Washington.

The Summit will be live streamed as per the agenda (US EST).  Individual videos of speaker presentations and the panel discussions will be added to the Summit app within 48 hours of the live event so delegates can watch/re-watch on-demand later.  The app will be live for 3 months after the event for all registered delegates.

Registered delegates will have access to the Summit video presentations and slides for 3 months post event via the Summit App.  After this date, we make these videos open access.  The 2022 Summit can be viewed HERE.

VIEW 2022 SUMMIT VIDEOS

SESSION 1: Evidence & Data

8:15 am - 8:20 am

Welcome

Chair

8:20 am - 8:50 am

OPENING KEYNOTE: Extended Session with Q&A

The Summit’s opening keynote will be delivered by  CTP Director, Dr Brian King and will include time for audience Q&A.  The FDA Center for Tobacco Products is responsible for carrying out the Family Smoking Prevention and Tobacco Control Act, which Congress passed in 2009. The Center makes decisions about whether new tobacco products and claims can be marketed, issues compliance and enforcement actions, educates the public about the risks of tobacco products, and issues rulemaking and guidance. Recently, the agency has undertaken steps to advance several key rules, including proposing tobacco product standards to prohibit menthol cigarettes and flavored cigars, as well as announcing its intent to propose a rule to establish a maximum level of nicotine in cigarettes and certain other combusted tobacco products. These actions have the potential to significantly reduce disease and death from combusted tobacco product use, the leading cause of preventable disease and death in the United States, by reducing youth experimentation and addiction, and increasing the number of smokers that quit. Additionally, these actions would represent an important step to advance health equity by significantly reducing tobacco-related health disparities.

Speaker

  • Dr Brian King Director, Center for Tobacco Products (CTP) - Food and Drug Administration (FDA)

8:50 am - 9:05 am

If vaping is a gateway to cigarette smoking, what are the implications?

With one exception, prospective studies have found that e-cigarette use by never-smoking adolescents increases their odds of trying combustible cigarettes 6-18 months later. Two meta-analyses concluded that the adjusted odds ratio was 3.5 or 4.6. This seems inconsistent with the fact that, in the US, adolescent cigarette smoking has declined at its fastest rate ever during e-cigarettes’ popularity. One possible explanation: vaping-associated smoking reflects trying cigarettes, without initiating sustained smoking. A new study challenges this conclusion, finding a statistically significant adjusted odds ratio of continued smoking two years after vaping-associated cigarette initiation. However, the study also finds the adjusted risk difference not statistically significant, reflecting very small absolute risks of continued smoking for those who have vaped and those who have not. This presentation translates the body of research into vaping’s implications for both subsequent committed smoking and its likely health impact.

Speaker

  • Prof Kenneth Warner Professor Emeritus and Dean Emeritus - School of Public Health, University of Michigan

9:05 am - 9:20 am

Past and future trends in nicotine-delivery product use and the need for a comprehensive approach

This talk focuses on US cigarette and alternative nicotine-delivery product use, and the potential impact of FDA regulations on their use. First, recent trends in cigarette, e-cigarette, oral nicotine pouch, and heated tobacco product use are presented. Trends in the use of individual products vary by age and depend on each of the other products. The potential role of the different products vis-a-vis reducing overall harm and the incentive of firms in promoting these products is then considered. Product use also depends on the impact of FDA regulations, especially their effect on flavor restrictions and the survival of cigarette vs. independent companies. A comprehensive approach towards the different nicotine-delivery products is needed, one that incorporates the impact of industry behavior and the role of innovation in the rapidly evolving US market.

Speaker

  • Prof David Levy Professor of Oncology - Lombardl Comprehensive Cancer Center, Georgetown University

9:20 am - 9:35 am

Effects of reduced-risk nicotine delivery products on smoking prevalence and on cigarette sales

It is currently not clear whether e-cigarettes and heated tobacco products are a gateway into smoking (e.g. by initiating young people into nicotine use and later smoking) or a gateway out of smoking (by replacing cigarettes on the population scale). We examined data on use and sales of cigarettes and the alternatives over time. The increase in heated tobacco product sales in Japan was accompanied by a decrease in cigarette sales. The decline in smoking prevalence has been slower in Australia where nicotine EC are banned than in the UK overall, and slower than in both the UK and USA among young people. The decline in cigarette sales has also accelerated faster in the UK than in Australia. No evidence emerged that alternative nicotine products are increasing smoking among young people or in the population generally. These findings have low certainty because of issues with pre-specified statistical assumptions and with available data.

Speaker

  • Prof Peter Hajek Professor of Clinical Psychology & Director of the Tobacco Dependence Research Unit - Wolfson Institute of Public Health, Queen Mary University of London

9:35 am - 9:50 am

Restrictions on sales of flavored nicotine and tobacco products in the US: Policy variation and impacts

While US states and municipalities have increasingly restricted the sales of flavored electronic nicotine delivery systems (ENDS), the literature on these laws’ effects remains fairly limited, with mixed results. Moreover, existing work largely focus on a single municipality or state’s policy changes. Consequently, published findings that appear to conflict with each other may in fact reflect differences in the policies being studied or their environments. To clarify ENDS flavor restrictions’ effects nationwide and their implications for public health, this talk will present new evidence on differences in flavor restriction policies across the US and their relationship to sales of cigarettes, cigars, and ENDS.

Speaker

9:50 am - 10:10 am

Panel Discussion and Q&A

Chair

Session Responder

Speakers

  • Prof Kenneth Warner Professor Emeritus and Dean Emeritus - School of Public Health, University of Michigan
  • Prof David Levy Professor of Oncology - Lombardl Comprehensive Cancer Center, Georgetown University
  • Prof Peter Hajek Professor of Clinical Psychology & Director of the Tobacco Dependence Research Unit - Wolfson Institute of Public Health, Queen Mary University of London
  • Associate Prof Abigail Friedman Associate Professor - Dept of Health Policy & Management, Yale School of Public Health

10:10 am - 10:30 am

Morning Refreshment Break

SESSION 2: Patterns of Use & Health Effects

10:30 am - 10:45 am

E-cigarettes and smoking cessation: A new twist on a familiar question

While debate on the role of e-cigarettes for tobacco control remains polarized, many of the concerns against them have been distorted. Randomized clinical trials offer the strongest evidence as to whether they can help smokers achieve abstinence from combustible products. Few such trials have been based in the US, where regulatory policy is still evolving. Study results complement and are largely consistent with the handful of clinical trials to assess causal effects of e-cigarettes on smoking cessation.  As a naturalistic randomized trial, the current study was aimed primarily to examine uptake of and outcomes from e-cigarettes, across a broad range of smokers given minimal guidance or instructions on use. Uptake was strong, with 70% of participants using the e-cigarette, with moderate frequency and amount. As a whole and with few exceptions, cessation and smoking reduction outcomes favored the e-cigarette group, even among smokers who expressed little interest in quitting at study outset. Growing evidence suggests that e-cigarettes can be a catalyst for smoking cessation, at least for some smokers. Current evidence suggests that this may be true even within unstructured and unguided use. This evidence must be balanced with the equally important public health need to minimize adolescent uptake of any form of nicotine, combustible and other. The US FDA has the regulatory authority to find this balance.

Speaker

  • Prof Matthew Carpenter Professor & Co-leader of the Cancer Control Program of the Hollings Cancer Center - Department of Psychiatry and Behavioral Sciences at the Medical University of South Carolina

10:45 am - 11:00 am

Are e-cigarettes less addictive than cigarettes and why does it matter?

Numerous studies find that people using e-cigarettes report themselves as being less addicted as compared to people using regular cigarettes. Similarly, PATH data shows that exclusive smokers have higher cotinine concentrations than exclusive e-cigarette users (although the gap narrows each year). So one reason e-cigarettes are generally less addictive could be that on average, they deliver less nicotine. However, some modern e-cigarettes are capable of delivering nicotine similarly to a cigarette, and even users of these products typically report lower dependence than smokers. Another factor could be that users have been using e-cigarettes for a shorter period of time than smokers (often decades shorter).  However, studies have found that while e-cigarette  dependence increases over the first few years of use, there is little or no change from years 4 through 8.  One possible reason that e-cigarettes appear less addictive, even when they have similar nicotine delivery capability to a cigarette, could relate to the very different puff topography associated with vaping versus smoking. Because the cigarette is on fire and will burn down, the smoker typically takes 8-12 puffs in a short time (4-10 minutes), achieving a blood nicotine boost around 15 ng/ml in 5 minutes. While some e-cigarettes are capable of the same, because it is not on fire, there is no need to take 8-12 puffs in 4-10 minutes before it burns your fingers. E-cigarette users learn that they can “graze”, intermittently toping up their nicotine levels with boosts of 2-5 ng/ml on a regular basis. It is possible that this different pattern of nicotine delivery is less addictive, for the similar reasons that the nicotine patch is much less addictive than the nicotine nasal spray. Why is it important? It is clear that e-cigarettes are addictive, but the fact that they are less so than cigarettes has important implications for long term health effects. Most smoking-caused diseases (e.g. cancer, COPD) are the result of decades of use and toxicant exposure. If a product is less addictive than a cigarette, the chances that a user will continue using the product on a daily basis (and be unable to quit) for decades is significantly lower. The estimate of the average harmfulness of e-cigarette use is a factor of the toxicant delivery multiplied by the years of use. If the daily toxicant delivery is 10% of that from a cigarette, and the average years of use is a quarter of that of a cigarette (e.g. 10 v 40 years), then the relative harm is 0.025 (or 2.5%). These numbers are estimates, simply designed to demonstrate the point that the addictiveness is an important determinant of lifetime exposure and harm..

Speaker

  • Prof Jonathan Foulds Professor Department of Public Health Sciences Division of Health Services and Behavioral Research - Penn State Center for Research on Tobacco and Health

11:00 am - 11:15 am

Inconvenient evidence: e-cigarettes for smoking cessation

Evidence has been a central tool in tobacco control for decades, and until recently, science and advocacy were easy partners – data clearly showed smoking killed, and tobacco control interventions saved lives. It has not been so straightforward for e-cigarettes, where data often sits less easily alongside emotions and philosophical stances. This doesn’t mean we need to move away from emotions and philosophy – they are central to achieving progress towards a smoke-free future. But it does mean we need to think carefully about why and how information is framed and interpreted. In this talk, I’ll present the latest results from the Cochrane review of e-cigarettes for smoking cessation, and reflect on the complex reactions it elicits

Speaker

  • Dr Jamie Hartmann-Boyce Associate Professor and Editor, Cochrane Tobacco Addiction Group - Nuffield Department of Primary Care Health Sciences, University of Oxford

11:15 am - 11:30 am

False risk perceptions and the use of harm as a deterrent

In this presentation, we look at the development of false risk perceptions about tobacco and nicotine products, where they come from, and who they hurt.  Because there is a persistent demand for nicotine based on its functional and hedonistic attributes, the demand for nicotine will persist. Without the significant harm associated with smoking, we will need to rethink the place of nicotine in society and alongside other recreational drugs. Without extreme harm and stigma as a deterrent, nicotine use in safer forms may even increase - but how much would that matter? The question we face is whether to manage the risks of nicotine use to an acceptably low level in a lawful regulated market or to try to control demand by limiting supply through regulation and prohibitions. Where does nicotine in its low-risk forms leave the complex of actors and interests that was built up over many decades to address smoking-related harms such as cancer, cardiovascular disease, and COPD?

Speaker

11:30 am - 11:45 am

Key differences and similarities of vaporized cannabis versus nicotine

Electronic vaping products emerged in the late 1990s as an alternative mode of cannabis use. Cannabis vaporizers were typically large devices that heated dried cannabis herb. In early 2000s, smaller portable vaporizers emerged as ‘e-cigarettes’ and those vaping products and have become the most popular mode of nicotine administration. E-cigarettes heat nicotine in a solution rather than from dried tobacco leaf, as was the case for the early vaporizers that utilized dried cannabis. Recently, vaporizers in the cannabis market have followed a similar transition, with greater use of liquid cannabis extracts. While smoking cannabis remains the most common method of use, alternative modes of delivery, such as the use of vaping devices, are becoming increasingly popular. This is expected to further expand as cannabis and tobacco companies partner to benefit from vaping technology. Many chemical constituents involved in vaping nicotine and cannabinoids are similar, and others are very different, lending importance to considering these issues in the context of understanding patterns of exposure and health consequences of vaping both substances. This presentation will aim to compare side-by-side the key differences and similarities of vaporized cannabis versus nicotine.

Speaker

  • Prof Maciej L. Goniewicz Professor of Oncology, Department of Health Behavior, Division of Cancer Prevention and Population Studies, - Roswell Park Comprehensive Cancer Center

11:45 am - 12:00 pm

Interactions between cannabis and nicotine use

In the U.S. among high school seniors the prevalence of past 30 day and daily vaping of nicotine and marijuana use are similar (20% and 6%). There is a high concordance of nicotine and cannabis (THC) use, with a significant correlation between magnitude of nicotine and THC exposure. Nicotinic cholinergic and endocannabinoid pathways interact in reward-related neural processes. In animals, THC promotes self-administration of nicotine. Among youth, cannabis users are more likely to take up cigarette smoking. In dual cannabis and tobacco product users, quitting cigarette smoking or quitting cannabis are more difficult. In dual users, mental health problems and cannabis use disorder are more common. Public health interventions to reduce nicotine vaping as well as cigarette smoking in youth will need to address the synergistic dependence-producing effects of cannabis and nicotine. Neal L. Benowitz MD – Professor of Medicine Emeritus (Active), University of California San Francisco, Zuckerberg San Francisco General Hospital

Speaker

12:00 pm - 12:30 pm

Panel Discussion and Q&A

Chair

Speakers

  • Prof Matthew Carpenter Professor & Co-leader of the Cancer Control Program of the Hollings Cancer Center - Department of Psychiatry and Behavioral Sciences at the Medical University of South Carolina
  • Prof Jonathan Foulds Professor Department of Public Health Sciences Division of Health Services and Behavioral Research - Penn State Center for Research on Tobacco and Health
  • Dr Jamie Hartmann-Boyce Associate Professor and Editor, Cochrane Tobacco Addiction Group - Nuffield Department of Primary Care Health Sciences, University of Oxford
  • Clive Bates Director - Counterfactual Consulting Ltd
  • Prof Maciej L. Goniewicz Professor of Oncology, Department of Health Behavior, Division of Cancer Prevention and Population Studies, - Roswell Park Comprehensive Cancer Center
  • Prof Neal L. Benowitz MD Professor of Medicine Emeritus (Active) - University of California, San Franciso

SESSION 3: Tobacco Control, Regulation & Policy

1:15 pm - 1:30 pm

Canada’s approach to vaping products and achieving <5% tobacco use by 2035

In 2018, Canada’s Tobacco Strategy (CTS) was introduced with the objective of achieving less than 5% tobacco use by 2035 (from the 2017 baseline of 18%). The most recent data from 2021 indicate that twelve percent of Canadians aged 15 years and older currently smoke, and tobacco use remains the leading preventable cause of death and disease, with approximately 48,000 Canadians dying from smoking-related illnesses every year. Canada’s Tobacco Strategy recognizes the potential of harm reduction – helping those who cannot or do not wish to quit using nicotine to identify less harmful options – while continuing to protect young people and those who do not use tobacco from inducements to use nicotine and tobacco. It also notes that tobacco use is not spread equally across the population and is often linked to other health and social inequities, requiring targeted approaches focussed on specific populations suffering from high levels of tobacco use. The presentation will highlight the progress made in achieving the CTS goal, with a focus on health inequities, and will examine the role of vaping products in achieving that goal. It will also examine the use of vaping products by youth, and the engagement of people with lived experience. *The Tobacco and Vaping Products Act (TVPA) came into force in May 2018, and along with other pieces of legislation, created a new legal framework for vaping products. Since its inception, regulations to address the increases of vaping use among youth were introduced, including a nicotine cap of 20mg/mL and a restriction on vaping product promotions. 

Speaker

  • Dr. Sonia Johnson Director General of the Tobacco Control Directorate - Health Canada

1:30 pm - 1:45 pm

Youth data on vaping and the UK approach

Changing your mind based on the facts is not changing your principles. The principle that ASH holds to is that a proportionate balance must be struck in the regulation of e-cigarettes, and other nicotine products, between helping adult smokers stop smoking, and preventing youth uptake of products which have the potential to be harmful and addictive. We believe that to ensure that principle is adhered to, it is vital to monitor and evaluate the evidence, so that our policy positions can be evidence-based. We started monitoring adult use of e-cigarettes in 2010 when it became obvious they were more than just a fad, and we started monitoring youth use in 2013, when concerns were first raised about their appeal to children. Our survey last year showed that youth use had grown significantly year on year, and we revised our policy positions in that light. This presentation will provide initial results from our 2023 adult and youth surveys, and demonstrate how the evidence is informing our policy recommendations to government.

Speaker

1:45 pm - 2:00 pm

Vaping and the smoking Endgame. Will New Zealand be smokefree in 2 years?

New Zealand has a smokefree goal to reduce smoking to under 5% by 2025. In December 2022 the government of Aotearoa New Zealand passed smoking endgame legislation that included the most aggressive tobacco control policy in the world. Laws will come into force by 2025 that reduce the retail supply of cigarettes by almost 90%, mandatory denicotinisation of cigarettes, and a ban on selling smoked tobacco to anyone born after January 2009. New Zealand has some of the most permissive vaping legislation in the world, and the last 3 years have seen record declines in adult and youth smoking rates. The government has been very clear that vaping has made aggressive policies on smoked tobacco a feasible option as the nations smokers can access viable alternates. This talk will outline the context for New Zealand’s endgame legislation and the tensions that exist between forced endgame policies and the role of vaping in achieving the goal. With only 2 years until New Zealand has some of the most restrictive smoked tobacco laws in the world, it will also examine perspectives around what proposed endgames policies might mean for public health, social justice and health equity.

Speaker

  • Ben Youdan Director - Youdan Consulting - New Zealand

2:00 pm - 2:30 pm

The role of tobacco regulatory approaches in addressing the evolving tobacco landscape

In this extended session, Kathy Crosby (Office of Health Communication) and Ben Apelberg (Office of Science) of the FDA’s CTP, will explore the evolving tobacco landscape in the U.S. and why shifting prevalence matters when working to protect public health via product review, regulations and public health education. Starting with the data, great gains have been realized due to the decline in smoking prevalence. However, an analysis of those still smoking shows the declines haven’t been equitable and health disparities exist, driving policy considerations. The session will then look at the increases in adult e-cigarette prevalence and explore where the increases are coming from and how that can impact public health. Finally, this session will discuss how regulatory actions evolve based on the data. Kathy will discuss misconceptions about nicotine and how current knowledge gaps are being explored via formative research to understand what smokers think about cessation, including the continuum of risk. Ben will close the session by exploring how consumer behaviors intersect with regulatory actions like product review and regulations.

Speakers

  • Kathleen Crosby Director, Office of Health Communication & Education - FDA Center for Tobacco Products
  • Benjamin Apelberg, Ph.D Deputy Director for Regulatory Science in the Office of Science - FDA’s Center for Tobacco Products (CTP)

2:30 pm - 2:45 pm

What doctors say…and what patients hear: Should e-cigarettes be more widely recommended as a smoking cessation aid?

The consequences of nicotine vaping are controversial, with two perspectives dominating the discussion: the risks of vaping for young people and the potential of vaping to increase smoking cessation among adults.  This session will focus specifically on the latter and consider how current scientific evidence is translated into clinical practice by healthcare professionals when discussing e-cigarettes with their patients who smoke.  Going beyond scientific evidence, the session will consider how clinicians’ actions are influenced by what medical and governmental authorities in various counties consider to be the appropriate role of e-cigarettes for adults who currently smoke. It will end with proposed recommendations for US clinicians.

Speaker

  • Dr. Nancy A. Rigotti, MD Professor of Medicine, Harvard Medical School - Director, Tobacco Research & Treatment Center, Massachusetts General Hospital, Boston

2:45 pm - 3:15 pm

Panel Discussion and Q&A

Chair

Speakers

  • Dr. Sonia Johnson Director General of the Tobacco Control Directorate - Health Canada
  • Deborah Arnott Chief Executive - Action on Smoking and Health (UK)
  • Ben Youdan Director - Youdan Consulting - New Zealand
  • Kathleen Crosby Director, Office of Health Communication & Education - FDA Center for Tobacco Products
  • Benjamin Apelberg, Ph.D Deputy Director for Regulatory Science in the Office of Science - FDA’s Center for Tobacco Products (CTP)
  • Dr. Nancy A. Rigotti, MD Professor of Medicine, Harvard Medical School - Director, Tobacco Research & Treatment Center, Massachusetts General Hospital, Boston

3:15 pm - 3:30 pm

Afternoon Refreshment Break

SESSION 4: Nicotine, Tobacco & Endgame

3:30 pm - 3:45 pm

What can we learn from historical events and US per-capita cigarette data from 1984 to present?

Many things have changed over the last ~40 years - this talk aims to look at big picture data to make sense cigarette use patterns in the United States.  Per-capita taxed cigarette data are used to show trends in relation to historical events from 1984 to present. Several sentinel events have occurred including industry consolidation, global economic crises, pandemics, unprecedented tobacco and nicotine product innovation, federal regulation of nicotine products, and a global treaty on tobacco control that led to a proliferation of global industry and public health actions and responses.  Results show steady declines in US per-capita taxed cigarettes across each decade throughout the entire period examined.  Implications will be explored to facilitate dialog.

Speaker

  • Andy Hyland Chair, Department of Health Behavior - Roswell Park Comprehensive Cancer Center

3:45 pm - 4:00 pm

E-cigarettes and mental health disorders: Opportunity or Concern?

Individuals with mental health or substance use disorders have disproportionately higher prevalence of smoking, greater levels of nicotine dependence, and worse health and quality of life outcomes than people without these conditions. Smokers with these disorders also have lower success with smoking cessation, even with evidence-based treatments. Thus, they remain a high priority population for more targeted interventions. This presentation will address whether e-cigarettes are an opportunity for harm reduction or helping smokers to quit, or whether they present additional concerns. Data on e-cigarette use among individuals with mental health conditions, their perceptions of e-cigarettes, and potential outcomes will be discussed, along with ways to maximize benefits. This presentation will also discuss the need for patient-centered, participatory designs in our research with these populations as a way of enhancing health equity, shared decision making, and movement away from paternalistic professional models that may exacerbate inequities.

Speaker

  • Prof Robin Mermelstein Distinguished Professor of Psychology and IHRP Director - University of Illinois, Chicago

4:00 pm - 4:15 pm

Tobacco Harm Reduction: What will (does) success look like?

From national goals (e.g., Healthy People 2030 in the US) to various formulations of so-called endgame strategies, concerned entities (governments, NGO’s) have described what might constitute success in terms of controlling and/or ending the tobacco and/or nicotine “epidemic.” Not surprisingly, such goals are not always clearly articulated, they change over time, and the processes by which they are formulated often remain opaque. As with most single-issue public health targets, their voice and force is diluted in the chorus of competing priorities. This relentless and rigid focus also obscures the contexts in which these problems occur. I will review recent (2021-22) US adult and adolescent tobacco use data to estimate current prevalence rates for use of nicotine and tobacco products. In addition, I will present these data in the context of other health and behavioral issues that co-occur with tobacco use (from the same surveys when possible). Not surprisingly, tobacco and nicotine product use is embedded within a constellation of other health and behavioral concerns, not all in the same ways, suggesting that success or failure of achieving tobacco control goals cannot and should not be isolated from the contexts in which they occur.

Speaker

  • Dr Ray Niaura Professor of Social & Behavioural Health & Co-Director of the Tobacco Research Lab - School of Global Public Health, New York University

4:15 pm - 4:30 pm

An international standard for vaping health risks research

To accelerate understanding of the contribution vaping can make to endgame strategies, we need more research. However, the quality of the research is critically important and this is particularly important when funding is limited. The UK's Office for Health Improvement and Disparities (OHID) e-cigarette health risk review findings were constrained largely because of the methodological limitations of the vaping studies we included. In relation to human studies examining health risks, particularly biomarkers, we believe that having international agreement on the following would be important moving forward: 1) examining relative risk of vaping compared with smoking, as well as absolute risk assessments; 2) strict definitions for people who exclusively smoke, exclusively vape, are concurrent users, used to smoke, or never smoked; 3) agreed definitions for exposure periods ; 4) the most rigorous study designs, follow-up periods and levels of adherence; 5) the most relevant biomarkers of exposure and harm to include. Setting up a standard around these issues and potentially other relevant criteria for vaping health risks research might improve the rigour of research in this field.  In this talk, drawing on the OHID review, some suggestions for the five issues above will be proposed.

Speaker

  • Professor Ann McNeill Professor of Tobacco Addiction - Institute of Psychiatry, Psychology & Neuroscience,, Kings College London

4:30 pm - 5:00 pm

CLOSING KEYNOTE: What Constitutes Success? A Dialogue on the “End State”

In this extended closing keynote session, Tom Glynn will moderate a dialogue with Cliff Douglas and Mitch Zeller on the potential “End State” for tobacco control efforts.  Rather than focusing on the pros or cons of various harm reduction approaches, Cliff and Mitch will describe the differences between potentially competing visions for what “success” looks like.  Is it a world that is tobacco-free?  Or one that is both tobacco-free and nicotine-free?  The discussion will explore the role of alternative and less harmful products, challenges posed by misperceptions of nicotine safety, and so-called “endgame” strategies such as mandated nicotine reduction in combustible tobacco products or a so-called “sinking lid” on allowable supplies of tobacco.

Chair

Speakers

  • Mitch Zeller J.D Director (Retired) Center for Tobacco Products (CTP) - The Food & Drug Administration (FDA)
  • Cliff Douglas, JD Director, Tobacco Research Network, Adjunct Professor, Department of Health Management and Policy - School of Public Health, University of Michigan

5:00 pm - 5:20 pm

Panel Discussion and Q&A

Chair

Speakers

  • Andy Hyland Chair, Department of Health Behavior - Roswell Park Comprehensive Cancer Center
  • Prof Robin Mermelstein Distinguished Professor of Psychology and IHRP Director - University of Illinois, Chicago
  • Dr Ray Niaura Professor of Social & Behavioural Health & Co-Director of the Tobacco Research Lab - School of Global Public Health, New York University
  • Professor Ann McNeill Professor of Tobacco Addiction - Institute of Psychiatry, Psychology & Neuroscience,, Kings College London
  • Mitch Zeller J.D Director (Retired) Center for Tobacco Products (CTP) - The Food & Drug Administration (FDA)
  • Cliff Douglas, JD Director, Tobacco Research Network, Adjunct Professor, Department of Health Management and Policy - School of Public Health, University of Michigan

5:20 pm - 5:25 pm

Closing Remarks from the Chair

Chair

5:25 pm - 6:15 pm

Summit End & Post Summit Drinks